Market Overview:
The global celiac disease drug market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of celiac disease, rising awareness about celiac disease and its treatment options, and the launch of novel drugs for the treatment of celiac disease. Based on type, the global celiac disease drug market can be segmented into distension, diarrhea, anorexia, and others. The distension segment is expected to account for the largest share of the global market in 2018 owing to its high prevalence among patients with celiac disease. Based on application, the global market can be divided into first line of treatment and second line of treatment.
Product Definition:
Celiac Disease Drug is a drug used to treat Celiac Disease. It is important because it helps people with Celiac Disease to digest food properly and avoid the health problems that can come from not being able to digest food properly.
Distension:
Distension is a generic term used for the process of growing larger in diameter as compared to it's original state. In the case of disease or injury, there are certain areas or organs that are stretched beyond their normal limits and if not treated at an early stage then they may have permanent damage.
In diseases such as cancer, there is often swelling due to increased blood flow (vasoactive) which can lead to permanent damage if not treated at an early stage.
Diarrhea:
Diarrhea is one of the most common gastrointestinal diseases globally. It is characterized by frequent and severe loose stools. The disease has two forms: acute and chronic diarrhea. Acute diarrhea usually lasts for more than 3 weeks, while chronic diarrhea continues for more than a month leading to low nutrient absorption in the body and can affect any individual irrespective of age, sex or immunity status.
Application Insights:
The first line of treatment segment held the largest market share in 2017 owing to the growing number of patients diagnosed with celiac disease and increasing awareness about available treatment options. Celiac disease is a lifelong condition which requires a lifelong medicine intake. Thus, patients considered as candidates for surgery are referred to surgeons for intestinal transplantation or other surgical procedures, while others require only medication throughout their life.
In 2017, second line of treatment emerged as the fastest-growing segment due to high usage rates and patient acceptance towards alternative treatments compared to surgery or no treatment at all.
Regional Analysis:
North America celiac disease drug market was valued at USD X million in 2017 and is expected to grow at a significant rate over the forecast period. This growth can be attributed to increasing awareness about gluten-free diet, rising prevalence of celiac disease, and presence of key players in the region. In addition, new product launches are also anticipated to boost regional market growth during the forecast period. For instance, Fycompa launched by Gilead Sciences LLC was approved for marketing in U.S.
Growth Factors:
- Increasing awareness about celiac disease and its symptoms
- Growing number of celiac patients
- Rising demand for gluten-free food products
- Technological advancements in the field of celiac disease diagnosis and treatment
- Government initiatives to promote gluten-free food products
Scope Of The Report
Report Attributes
Report Details
Report Title
Celiac Disease Drug Market Research Report
By Type
Distension, Diarrhea, Anorexia, Others
By Application
First Line of Treatment, Second Line of Treatment
By Companies
F. Hoffmann-La Roche, Johnson & Johnson, Merck, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, F. Hoffmann-La Roche, Bristol-Myers Squibb, Celgene, Takeda Pharmaceutical, Novartis, LFB Group, Kedrion Biopharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Celiac Disease Drug Market Report Segments:
The global Celiac Disease Drug market is segmented on the basis of:
Types
Distension, Diarrhea, Anorexia, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
First Line of Treatment, Second Line of Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Johnson & Johnson
- Merck
- Pfizer
- ADMA Biologics
- Amgen
- Anthera Pharmaceuticals
- Bayer
- Biogen
- BioLineRx
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- Celgene
- Takeda Pharmaceutical
- Novartis
- LFB Group
- Kedrion Biopharma
Highlights of The Celiac Disease Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Distension
- Diarrhea
- Anorexia
- Others
- By Application:
- First Line of Treatment
- Second Line of Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Celiac Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Celiac disease drug is a medication used to treat celiac disease. It helps to reduce the symptoms of the condition, such as diarrhea, constipation, bloating, and pain.
Some of the major companies in the celiac disease drug market are F. Hoffmann-La Roche, Johnson & Johnson, Merck, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, F. Hoffmann-La Roche, Bristol-Myers Squibb, Celgene, Takeda Pharmaceutical, Novartis, LFB Group, Kedrion Biopharma.
The celiac disease drug market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Celiac Disease Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Celiac Disease Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Celiac Disease Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Celiac Disease Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Celiac Disease Drug Market Size & Forecast, 2020-2028
4.5.1 Celiac Disease Drug Market Size and Y-o-Y Growth
4.5.2 Celiac Disease Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Distension
5.2.2 Diarrhea
5.2.3 Anorexia
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 First Line of Treatment
6.2.2 Second Line of Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Celiac Disease Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Celiac Disease Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Distension
9.6.2 Diarrhea
9.6.3 Anorexia
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 First Line of Treatment
9.10.2 Second Line of Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Distension
10.6.2 Diarrhea
10.6.3 Anorexia
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 First Line of Treatment
10.10.2 Second Line of Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Distension
11.6.2 Diarrhea
11.6.3 Anorexia
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 First Line of Treatment
11.10.2 Second Line of Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Distension
12.6.2 Diarrhea
12.6.3 Anorexia
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 First Line of Treatment
12.10.2 Second Line of Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Distension
13.6.2 Diarrhea
13.6.3 Anorexia
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 First Line of Treatment
13.10.2 Second Line of Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Celiac Disease Drug Market: Competitive Dashboard
14.2 Global Celiac Disease Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche
14.3.2 Johnson & Johnson
14.3.3 Merck
14.3.4 Pfizer
14.3.5 ADMA Biologics
14.3.6 Amgen
14.3.7 Anthera Pharmaceuticals
14.3.8 Bayer
14.3.9 Biogen
14.3.10 BioLineRx
14.3.11 F. Hoffmann-La Roche
14.3.12 Bristol-Myers Squibb
14.3.13 Celgene
14.3.14 Takeda Pharmaceutical
14.3.15 Novartis
14.3.16 LFB Group
14.3.17 Kedrion Biopharma
